Monopar Therapeutics MNPR Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Monopar Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Monopar Therapeutics's current ratio?
- Monopar Therapeutics (MNPR) reported current ratio of 56× in Q1 2026.
- What is the long-term trend for Monopar Therapeutics's current ratio?
- Over 5 years (2020 to 2025), Monopar Therapeutics's current ratio has grown at a 29.2% compound annual growth rate (CAGR), from 14.3× to 51.4×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.